Skip to content
The GLP-1 Verdict
Menu

Evidence review

Semaglutide vs Tirzepatide: Which Is Right for You?

Tirzepatide wins on raw weight loss in the trials; semaglutide is the longer-established, often cheaper option. Here is how to decide between them.

By The Verdict Desk, Provider Review Board

If you only remember one thing: tirzepatide produced more weight loss than semaglutide in the trials, but "more" is not automatically "right for you." Price, dosing, side-effect tolerance, and how your body responds all bend the decision. Here is the evidence, stated plainly, then how to choose.

What each molecule is

Semaglutide is a GLP-1 receptor agonist — it mimics one gut hormone that curbs appetite and slows gastric emptying. Tirzepatide is a dual agonist: it hits both the GLP-1 and GIP receptors. That second mechanism is the leading explanation for why tirzepatide tends to drive more weight loss.

The efficacy evidence

The cleanest way to read the numbers is trial by trial.

Semaglutide, in the STEP-1 obesity trial, produced a mean body-weight reduction of roughly 15% over 68 weeks at the 2.4 mg weekly dose1. That result underpins the FDA approval of Wegovy for chronic weight management2.

Tirzepatide, in SURMOUNT-1, went further: about 15% at 5 mg, and roughly 20–21% at the 15 mg dose over 72 weeks3. That result underpins the FDA approval of Zepbound4.

The most direct comparison comes from SURPASS-2, a head-to-head trial in adults with type 2 diabetes. There, tirzepatide beat semaglutide 1 mg on both blood-sugar control and weight reduction5. It is a diabetes trial rather than an obesity trial, so read it as directional for weight — but the direction is consistent: tirzepatide tends to win on magnitude.

So why would anyone pick semaglutide?

Because raw magnitude is one variable, not the only one.

**Price.** On our board, compounded semaglutide is frequently the cheaper molecule, and for many people the gap funds months of treatment. See what compounded GLP-1 costs per month.

**Track record.** Semaglutide has been in widespread use longer, which some people weigh heavily.

**Tolerability.** Both cause GI side effects — nausea, constipation — that ease with slow titration. Individuals tolerate the two differently; the "better" molecule is partly the one your body handles.

**Availability.** Depending on your provider and state, one molecule may simply be easier to get.

How to choose

Choose **tirzepatide** if maximum weight loss is the priority, the price premium is acceptable, and you tolerate titration well. It is the stronger performer on the trial evidence.

Choose **semaglutide** if cost is decisive, you prefer the longer-established option, or your provider prices it more aggressively. It is a proven, powerful drug in its own right — STEP-1's ~15% is not a consolation prize.

And remember you are not married to the choice: the best move is often to start on one and keep the option to switch. Providers with both molecules on a single account make that painless — which is exactly why formulary breadth is a scored factor in our Verdict Score methodology. Compare who offers what in the reviews, and if you are still deciding between compounded and brand, read compounded vs brand-name GLP-1.

This is editorial information, not medical advice. Which molecule and dose is right for you is a decision for you and a licensed clinician.

Frequently asked questions

Which causes more weight loss?

Tirzepatide reached about 20–21% at its top dose in SURMOUNT-1 versus roughly 15% for semaglutide in STEP-1, and it beat semaglutide 1 mg head-to-head in the SURPASS-2 diabetes trial.

Can I switch between them?

Many people do, guided by a clinician. Providers that carry both molecules on one account make switching easier, which is why formulary breadth is part of our Verdict Score.

Is one safer than the other?

Both share similar GI side effects that ease with slow titration and carry the same class warnings. Tolerance is individual. Discuss your history with a licensed clinician.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. U.S. Food and Drug Administration (2021). Wegovy (semaglutide) injection — Drugs@FDA prescribing information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  4. U.S. Food and Drug Administration (2023). Zepbound (tirzepatide) injection — Drugs@FDA prescribing information. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
  5. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/34170647/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.